| Title |
BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
|
|---|---|
| Published in |
PLOS ONE, January 2012
|
| DOI | 10.1371/journal.pone.0030042 |
| Pubmed ID | |
| Authors |
Weiya Z. Wysham, Paulette Mhawech-Fauceglia, Hong Li, Laura Hays, Suzanna Syriac, Tijana Skrepnik, Jay Wright, Nupur Pande, Maureen Hoatlin, Tanja Pejovic |
| Abstract |
The consequences of defective homologous recombination (HR) are not understood in sporadic ovarian cancer, nor have the potential role of HR proteins other than BRCA1 and BRCA2 been clearly defined. However, it is clear that defects in HR and other DNA repair pathways are important to the effectiveness of current therapies. We hypothesize that a subset of sporadic ovarian carcinomas may harbor anomalies in HR pathways, and that a BRCAness profile (defects in HR or other DNA repair pathways) could influence response rate and survival after treatment with platinum drugs. Clinical availability of a BRCAness profile in patients and/or tumors should improve treatment outcomes. |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Spain | 1 | 1% |
| Nigeria | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 76 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 30% |
| Student > Ph. D. Student | 12 | 15% |
| Student > Master | 9 | 11% |
| Professor > Associate Professor | 6 | 7% |
| Student > Postgraduate | 5 | 6% |
| Other | 18 | 22% |
| Unknown | 7 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 38% |
| Agricultural and Biological Sciences | 24 | 30% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Chemistry | 3 | 4% |
| Other | 6 | 7% |
| Unknown | 8 | 10% |